Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Pharmacoeconomics|June 10, 2006
The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathyGeorge W Carides, Shahnaz Shahinfar, Erik J Dasbach, et al.
American Journal of Therapeutics|August 1, 1994
Disposition of Misoprostol and Its Active Metabolite in Impaired Hepatic FunctionEdward F. Foote, William R. Garnett, Daniel R. Lee, et al.
Circulation|August 11, 2004
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathyDick de Zeeuw, Giuseppe Remuzzi, Hans-Henrik Parving, et al.
Kidney International|May 20, 2004
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAALDick de Zeeuw, Giuseppe Remuzzi, Hans-Henrik Parving, et al.
Diabetes Care|March 1, 2003
Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluationWilliam H Herman, Shahnaz Shahinfar, George W Carides, et al.
Kidney International|March 23, 2005
Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation ProgramTarek M El-Achkar, Suzanne E Ohmit, Peter A McCullough, et al.
Journal of the American Society of Nephrology : JASN|May 6, 2005
Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) studyZhongxin Zhang, Shahnaz Shahinfar, William F Keane, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 28, 2003
Early detection of kidney disease in community settings: the Kidney Early Evaluation Program (KEEP)Wendy Weinstock Brown, Rosalind M Peters, Suzanne E Ohmit, et al.
Diabetes Care|December 12, 2007
Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL studyAndrew M Tershakovec, William F Keane, Zhongxin Zhang, et al.
Kidney International|March 13, 2003
The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL studyWilliam F Keane, Barry M Brenner, Dick de Zeeuw, et al.
Pageof 3